BRAIN Biotech AG (HAM:BNN) Moat Score: 0/10 (As of Jul. 07, 2026)


HAM:BNN BRAIN Biotech AG HAM:BNN
66 GF Score
Price €2.74
GF Value €2.48
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Moat Score?

BRAIN Biotech AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

BRAIN Biotech AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BRAIN Biotech AG might have No Moat - No discernible moat.

BRAIN Biotech AG  (HAM:BNN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BRAIN Biotech AG Moat Score Related Terms

HAM:BNN
66GF Score
BRAIN Biotech AG HAM:BNN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.74 is trading 10.5% above its estimated GF Value™ of €2.48. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Moat Score: 0
  • GF Value™: €2.48 vs. price of €2.74 (10.5% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score

Get the complete analysis for HAM:BNN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price
€2.48
GF Value